A number of ATP-competitive mTOR inhibitors are now reaching the clinical phase of development in other disease contexts (including equally fatal conditions such as cancer44), we therefore extended our analysis to determine the impact of ATP-competitive mTOR inhibition on other TGF-β1 regulated matrisome proteins in IPF-derived fibroblasts by comparing the effect of CZ415 (the most potent and selective ATP-competitive mTOR inhibitor tested, Supplementary Fig. 2) with rapamycin. The gene discussed is MTOR; the disease is idiopathic pulmonary fibrosis.